Myriad Genetics, Inc. (MYGN)
4.50
-0.04
(-0.88%)
USD |
NASDAQ |
Jun 22, 16:00
4.50
0.00 (0.00%)
After-Hours: 20:00
Myriad Genetics Cash from Financing (Quarterly) : -3.00M for March 31, 2026
Cash from Financing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | -3.00M |
| December 31, 2025 | -8.20M |
| September 30, 2025 | 56.20M |
| June 30, 2025 | 2.60M |
| March 31, 2025 | 13.60M |
| December 31, 2024 | 2.10M |
| September 30, 2024 | -3.10M |
| June 30, 2024 | 2.40M |
| March 31, 2024 | -8.80M |
| December 31, 2023 | 121.90M |
| September 30, 2023 | -2.50M |
| June 30, 2023 | 38.40M |
| March 31, 2023 | -4.90M |
| December 31, 2022 | -2.10M |
| September 30, 2022 | -2.90M |
| June 30, 2022 | 2.50M |
| March 31, 2022 | -4.80M |
| December 31, 2021 | -1.10M |
| September 30, 2021 | -74.50M |
| June 30, 2021 | -26.50M |
| March 31, 2021 | -47.30M |
| June 30, 2020 | 2.00M |
| March 31, 2020 | 0.20M |
| December 31, 2019 | 1.10M |
| September 30, 2019 | -12.30M |
| Date | Value |
|---|---|
| June 30, 2019 | -27.80M |
| March 31, 2019 | -9.40M |
| December 31, 2018 | -32.60M |
| September 30, 2018 | 252.10M |
| June 30, 2018 | -41.30M |
| March 31, 2018 | -4.50M |
| December 31, 2017 | -26.40M |
| September 30, 2017 | -23.30M |
| June 30, 2017 | -63.30M |
| March 31, 2017 | -36.70M |
| December 31, 2016 | -4.00M |
| September 30, 2016 | 175.80M |
| June 30, 2016 | -46.30M |
| March 31, 2016 | -60.10M |
| December 31, 2015 | 48.40M |
| September 30, 2015 | -10.30M |
| June 30, 2015 | -40.19M |
| March 31, 2015 | -55.98M |
| December 31, 2014 | -52.27M |
| September 30, 2014 | -28.85M |
| June 30, 2014 | -42.05M |
| March 31, 2014 | 3.421M |
| December 31, 2013 | -71.66M |
| September 30, 2013 | -101.51M |
| June 30, 2013 | 13.38M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Financing (Quarterly) Benchmarks
| Natera, Inc. | 3.758M |
| BioRestorative Therapies, Inc. | 4.441M |
| CareDx, Inc. | -2.911M |
| Exagen, Inc. | -0.062M |
| Sera Prognostics, Inc. | 0.02M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -15.70M |
| Cash from Investing (Quarterly) | -6.50M |
| Free Cash Flow | -23.20M |
| Free Cash Flow Per Share (Quarterly) | -0.2369 |
| Free Cash Flow to Equity (Quarterly) | -23.90M |
| Free Cash Flow to Firm (Quarterly) | -18.10M |
| Free Cash Flow Yield | -5.53% |